Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
31 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/31/3211828/0/en/Total-number-of-shares-and-voting-rights-in-Zealand-Pharma-as-of-December-31-2025.html
19 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/19/3208722/0/en/Transactions-in-Zealand-Pharma-shares-and-or-related-securities-by-persons-discharging-managerial-responsibilities-and-or-their-closely-associated-persons.html
11 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3203616/0/en/Zealand-Pharma-and-OTR-Therapeutics-enter-multi-program-strategic-collaboration-and-license-agreement-to-develop-novel-therapeutics-for-metabolic-diseases.html
11 Dec 2025
// REUTERS
https://www.reuters.com/sustainability/boards-policy-regulation/zealand-pharma-accelerate-drug-development-obesity-metabolic-disease-2025-12-11/
11 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3204280/0/en/Zealand-Pharma-increases-its-share-capital-as-a-result-of-the-exercise-of-employee-warrants.html
11 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3203618/0/en/Zealand-Pharma-outlines-Metabolic-Frontier-2030-strategy-to-become-a-generational-biotech-leader-in-obesity-and-metabolic-health.html
Drugs in Development
Details:
The collaboration aims to advance the development of a new treatment for metabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Miscellaneous
Recipient: OTR Therapeutics
Deal Size: $2,500.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration December 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Recipient : OTR Therapeutics
Deal Size : $2,500.0 million
Deal Type : Collaboration
Zealand Pharma, OTR Therapeutics Collaborate on Metabolic Treatment
Details : The collaboration aims to advance the development of a new treatment for metabolic diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $20.0 million
December 11, 2025
Details:
ZP1848 (glepaglutide) is a peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Glepaglutide
Therapeutic Area: Gastroenterology Brand Name: ZP1848
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2025
Lead Product(s) : Glepaglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation of Glepaglutide in Treatment of SBS
Details : ZP1848 (glepaglutide) is a peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : ZP1848
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 14, 2025
Details:
Glepaglutide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Glepaglutide
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2025
Lead Product(s) : Glepaglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Details : Glepaglutide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 30, 2025
Details:
Petrelintide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Diseases.
Lead Product(s): Petrelintide
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Icon Plc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Petrelintide in Participants with Impaired Renal Function
Details : Petrelintide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 20, 2025
Details:
ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Lead Product(s): Petrelintide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Enrolls First in ZUPREME-2 Trial of Petrelintide for Obesity And T2D
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 24, 2025
Details:
Petrelintide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Overweight.
Lead Product(s): Petrelintide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Parexel
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Petrelintide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Overweight.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 15, 2025
Details:
ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Lead Product(s): Petrelintide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Completes Phase 2b Enrollment for Petrelintide in Obesity
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 17, 2025
Details:
The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Lead Product(s): Petrelintide,CT-388
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Peptide, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: $5,300.0 million Upfront Cash: $1,650.0 million
Deal Type: Collaboration March 12, 2025
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy
Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $1,650.0 million
March 12, 2025
Details:
Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Lead Product(s): Dapiglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Profil Institut für Stoffwechselforschung GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2025
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dapiglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 06, 2025
Details:
ZP1848 (glepaglutide) is a long-acting GLP-2 analog synthetic peptide, which is currently being evaluated for the treatment of patients with short bowel syndrome.
Lead Product(s): Glepaglutide
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Glepaglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Issues Complete Response Letter for Glepaglutide NDA for Short Bowel Syndrome
Details : ZP1848 (glepaglutide) is a long-acting GLP-2 analog synthetic peptide, which is currently being evaluated for the treatment of patients with short bowel syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 19, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
